Transforming growth factor beta and progression of renal disease

Slides:



Advertisements
Similar presentations
Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages
Advertisements

Stephen P. McDonald, Graeme R. Russ  Kidney International 
Volume 54, Issue 2, Pages (August 1998)
Volume 61, Issue 1, Pages (January 2002)
MariLia Bahiense Oliveira, Joao Egidio Romao, Roberto Zatz 
Cellular mechanisms of renal osteodystrophy
Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh  Kidney International 
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
Volume 83, Issue 3, Pages (March 2013)
Volume 58, Issue 4, Pages (October 2000)
Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh  Kidney International 
Volume 56, Pages S31-S36 (July 1999)
Progression of renal failure and hypertensive nephrosclerosis
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Burden of chronic kidney disease: North Africa
Volume 54, Issue 2, Pages (August 1998)
Haiyan Wang, Luxia Zhang, Jicheng Lv  Kidney International 
Francesco Paolo Schena  Kidney International 
Sudha K. Iyengar, Jeffrey R. Schelling, John R. Sedor 
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Comorbidity and confounding in end-stage renal disease
Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson 
Survival advantage in Asian American end-stage renal disease patients1
Volume 70, Issue 11, Pages (December 2006)
Insulin resistance in African Americans
The epidemiology of chronic kidney disease
Reciprocal functions of hepatocyte growth factor and transforming growth factor-β1 in the progression of renal diseases: A role for CD44?  Sandrine Florquin,
The role of protein kinase C activation in diabetic nephropathy
Study of Heart and Renal Protection (SHARP)
Volume 71, Issue 6, Pages (March 2007)
Saulo Klahr, Jeremiah J. Morrissey  Kidney International 
Volume 70, Issue 12, Pages (December 2006)
Proteinuria and hypertensive nephrosclerosis in African Americans
Elevated risk of stroke among patients with end-stage renal disease
Atrial fibrillation in end-stage renal disease: an emerging problem
Volume 60, Issue 1, Pages (July 2001)
Counteracting progression of renal disease: A look into the future
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Arjang Djamali, Christina Kendziorski, Peter C. Brazy, Bryan N. Becker 
Homocysteine, renal function, and risk of cardiovascular disease
Volume 67, Issue 5, Pages (May 2005)
E.A. Friedman, A.L. Friedman, P. Eggers  Kidney International 
Volume 72, Issue 4, Pages (August 2007)
Why is proteinuria an ominous biomarker of progressive kidney disease?
Stephen P. McDonald, Graeme R. Russ  Kidney International 
Volume 82, Issue 9, Pages (November 2012)
Volume 64, Issue 2, Pages (August 2003)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial 
Unraveling the racial disparities associated with kidney disease1
Peritoneal dialysis in Mexico
Volume 76, Issue 1, Pages (July 2009)
Volume 61, Issue 2, Pages (February 2002)
Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program  Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.
Clinical benefits of slowing the progression of renal failure
Low triiodothyronine and survival in end-stage renal disease
Volume 55, Pages S3-S16 (June 1999)
Volume 80, Issue 10, Pages (November 2011)
Is it the low-protein diet or simply the salt restriction?
Charles A. Herzog  Kidney International 
Volume 56, Issue 2, Pages (August 1999)
Volume 66, Pages S7-S10 (November 2004)
Renal replacement therapy in Latin America
Volume 75, Issue 7, Pages (April 2009)
Volume 70, Issue 10, Pages (November 2006)
Lipoprotein abnormalities in diabetic nephropathy
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Presentation transcript:

Transforming growth factor beta and progression of renal disease Phyllis August, Manikkam Suthanthiran  Kidney International  Volume 64, Pages S99-S104 (November 2003) DOI: 10.1046/j.1523-1755.64.s87.15.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Differential level of expression of transforming growth factor beta 1 (TGF-β1) protein in African American ESRD patients and white ESRD patients. (A) The mean ± SEM TGF-β1 protein level was 207 ± 10ng/mL in African American ESRD patients (N = 52) and 137 ± 8ng/mL in white ESRD patients (N = 46). (B) The frequency distribution of TGF-β1 levels in the ESRD patients, distinguished by race. TGF-β1 values (96%) from African American ESRD patients were within 2 SD of the mean value, and the coefficient of skewness and the coefficient of kurtosis were 0.20 and 0.24, respectively; 93% of the TGF-β1 values from white ESRD patients were within 2 SD of the mean value, and the coefficient of skewness and the coefficient of kurtosis were 0.38 and 0.78, respectively. In view of the normal distribution of TGF-β1 values in the African American as well as white ESRD patients, Student t test was used to derive the P value shown. Kidney International 2003 64, S99-S104DOI: (10.1046/j.1523-1755.64.s87.15.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Transforming growth factor β1 (TGF-β1) mRNA steady state levels in hypertensives and normotensives. The mean ± SEM TGF-β1 mRNA/GAPDH mRNA ratios, calculated after quantification of mRNA levels in peripheral blood mononuclear cells (PBMC) were 3.35 ± 0.81 and 4.51 ± 0.69 in normotensives (N) and hypertensives (HT), respectively (P < 0.04, Mann-Whitney two-sample test). Kidney International 2003 64, S99-S104DOI: (10.1046/j.1523-1755.64.s87.15.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Hypothetical model of transforming growth factor beta 1 (TGF-β1) hyperexpression as a contributory factor for progressive renal insufficiency. In this hypothesis for the pathogenesis of progressive renal insufficiency, patients expressing high levels of TGF-β1 in response to renal injury are at an increased risk for progression. In this formulation, TGF-β1 expression is engendered by the primary insult (e.g., diabetes), and progressive renal insufficiency results from the heightened expression of TGF-β1. Abbreviations are: DM, diabetes mellitus; GN, glomerulonephritis; HT, hypertension; ESRD, end-stage renal disease. Kidney International 2003 64, S99-S104DOI: (10.1046/j.1523-1755.64.s87.15.x) Copyright © 2003 International Society of Nephrology Terms and Conditions